- Home
- AUPH vs SANA Comparison
AUPH vs SANA Comparison
Compare AUPH & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AUPH | SANA |
|---|---|---|
| Founded | 1993 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 1999 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AUPH | SANA |
|---|---|---|
| Price | $14.78 | $5.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $17.25 | $7.83 |
| AVG Volume (30 Days) | 939.1K | ★ 2.5M |
| Earning Date | 02-26-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $265,808,000.00 | N/A |
| Revenue This Year | $21.76 | N/A |
| Revenue Next Year | $16.45 | N/A |
| P/E Ratio | $27.01 | ★ N/A |
| Revenue Growth | ★ 20.62 | N/A |
| 52 Week Low | $6.55 | $1.26 |
| 52 Week High | $16.54 | $6.55 |
Technical Indicators
Market Signals| Indicator | AUPH | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 40.82 | 61.93 |
| Support Level | $14.36 | $4.36 |
| Resistance Level | $15.19 | $5.20 |
| Average True Range (ATR) | 0.49 | 0.34 |
| MACD | -0.09 | 0.05 |
| Stochastic Oscillator | 24.06 | 83.61 |
Price Performance
Historical ComparisonAbout AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.